ID: MRFR/Pharma/4863-HCR | 100 Pages | Published By Rahul Gotadki on April 2023
The alagille syndrome global market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The alagille syndrome market in the Middle East & Africa has been segmented into the Middle East and Africa.
Sanofi AG, Teva Pharmaceutical Industries Ltd., Allergen Plc, Lannett, Albireo Pharma, Inc., AstraZeneca Plc, Novartis AG, Pfizer, Inc., Shire, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc. are some of the key players in the global alagille syndrome market.
Regional Market Summary
Global Alagille Syndrome Market Share (%), by Region, 2017
Source: MRFR Analysis
Geographically, the Americas is anticipated to dominate the global alagille syndrome market owing to a well-developed healthcare sector, rising prevalence of rare genetic disease and growing healthcare expenditure. According to the Global Genes Project, rare and genetic diseases affect 1 in 10 people in the United States Additionally, increasing awareness among the people regarding the disease and well-developed technology is likely to contribute to the growth of the market.
Europe is expected to hold the second largest position in the alagille syndrome global market. The market growth in this region is attributed to the growing prevalence of several liver diseases, increasing prevalence of genetic disease, availability of funds for research, and increasing healthcare expenditure. According to the Public Health England, approximately 11,597 number of people died with an underlying cause of liver disease in England in 2014. In addition, according to the Office for National Statistics, gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in 2016.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, growing occurrences of rare diseases and increasing government funding for the healthcare sector.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Global Alagille Syndrome Market, by Symptom
Global Alagille Syndrome Market, by Treatment
Global Alagille Syndrome Market, by Diagnosis
Global Alagille Syndrome Market, by End-User
Global Alagille Syndrome Market, by Region
|Market Size||Significant Value|
|CAGR||2022-2030: 5.90% CAGR|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Symptom, Treatment, Diagnosis, And End-User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Sanofi AG, Teva Pharmaceutical Industries Ltd., Allergen Plc, Lannett, Albireo Pharma, Inc., AstraZeneca Plc, Novartis AG, Pfizer, Inc., Shire, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc|
|Key Market Opportunities||Increasing government funding for the healthcare sector|
|Key Market Drivers||
Alagille market may suffer a setback due to a lack of awareness.
Symptoms included in the alagille syndrome market are nutrition problems, liver problems, distinctive facial features, neurologic problems, heart problems, and others.
The segments in alagille syndrome market report are biliary diversion procedures, medication, liver transplantation, vitamin supplements, heart surgery, kidney surgery, and others.
The segments included in alagille syndrome market report are urinalysis, prenatal DNA testing, blood test, slit-lamp exam, X-ray imaging, cardiology exam, genetic testing, liver biopsy, and others.
The end users involved in alagille syndrome market report are diagnostic centers, hospitals & clinics, and others.